Neurology and Therapy (Jun 2023)
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
Abstract
Abstract This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB)
Keywords